Expression of PTEN and KAI1 tumor suppressor genes in pancreatic carcinoma and its association with different pathological factors

Huang,Weidong; Yang,Jie; Ren,Jun; Tang,Jianjun

doi:10.3892/ol.2015.3932

Expression of PTEN and KAI1 tumor suppressor genes in pancreatic carcinoma and its association with different pathological factors

Authors:
- Weidong Huang
- Jie Yang
- Jun Ren
- Jianjun Tang
View Affiliations

Affiliations: Department of General Surgery, Xiangyang Hospital Affiliated to Hubei University of Medicine, Xiangyang, Hubei 441000, P.R. China
Published online on: November 17, 2015 https://doi.org/10.3892/ol.2015.3932
Pages: 559-562
Copyright: © Huang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Pancreatic carcinoma is a common cancer type with a poor prognosis. The aim of the present study was to examine the expression of tumor suppressor genes phosphatase and tensin homolog deleted in chromosome 10 (PTEN) and KAI1 in pancreatic carcinoma and its association with clinical pathological factors. A total of 50 hospitalized cases of pancreatic cancer including 28 males and 22 females aged 31‑82 years were included in the present study. Ten cases of normal pancreatic tissue were obtained from cadavers and served as the controls. The pancreatic specimens were embedded in paraffin blocks and slides were prepared for immunohistochemical analysis to determine the expression of PTEN and KAI1 in normal pancreatic tissue and pancreatic carcinoma samples. The positive expression rate of PTEN in the normal pancreatic tissue was higher than that in pancreatic carcinoma (P<0.05), while the positive expression rate of KAI1 in the normal pancreatic tissue was lower than that in pancreatic carcinoma (P<0.05). Pathological factors such as clinical stage of disease, histological grade and the presence or absence of lymphatic metastasis significantly affected the expression of PTEN and KAI1 (P<0.05). In conclusion, the positive expression of PTEN and KAI1 in pancreatic carcinoma is closely associated with the development of pancreatic carcinoma.

View Figures

View References

1	Li Destri G, Giarrizzo A, Bellavia N, Milazzotto R, Frattalone ME, Scilletta B and Di Cataldo A: Synchronous double cancers of the colon and the pancreas: a case report. Eur Rev Med Pharmacol Sci. 18(Suppl 2): 28–31. 2014.PubMed/NCBI
2	Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, Puc J, Miliaresis C, Rodgers L, McCombie R, et al: PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science. 275:1943–1947. 1997. View Article : Google Scholar : PubMed/NCBI
3	Costa HA, Leitner MG, Sos ML, Mavrantoni A, Rychkova A, Johnson JR, Newton BW, Yee MC, De La Vega FM, Ford JM, Krogan NJ, Shokat KM, Oliver D, Halaszovich CR and Bustamante CD: Discovery and functional characterization of a neomorphic PTEN mutation. Proc Natl Acad Sci USA. 112:13976–13981. 2015. View Article : Google Scholar : PubMed/NCBI
4	Maccioni F, Martinelli M, Al Ansari N, Kagarmanova A, De Marco V, Zippi M and Marini M: Magnetic resonance cholangiography: past, present and future: a review. Eur Rev Med Pharmacol Sci. 14:721–725. 2010.PubMed/NCBI
5	Squadroni M and Fazio N: Chemotherapy in pancreatic adenocarcinoma. Eur Rev Med Pharmacol Sci. 14:386–394. 2010.PubMed/NCBI
6	Hermanek P and Sobin LH: International Union Against Cancer (UICC): TNM Classification of Malignant Tumours (4th). New York, NY: Springer. 712731992.
7	Depowski PL, Rosenthal SI and Ross JS: Loss of expression of the PTEN gene protein product is associated with poor outcome in breast cancer. Mod Pathol. 14:672–676. 2001. View Article : Google Scholar : PubMed/NCBI
8	Jiang J, Li Z, Yu C, Chen M, Tian S and Sun C: MiR-1181 inhibits stem cell-like phenotypes and suppresses SOX2 and STAT3 in human pancreatic cancer. Cancer Lett. 356(2 Pt B): 962–970. 2015. View Article : Google Scholar : PubMed/NCBI
9	Morran DC, Wu J, Jamieson NB, Mrowinska A, Kalna G, Karim SA, Au AY, Scarlett CJ, Chang DK, Pajak MZ, et al: Australian Pancreatic Cancer Genome Initiative (APGI): Targeting mTOR dependency in pancreatic cancer. Gut. 63:1481–1489. 2014. View Article : Google Scholar : PubMed/NCBI
10	Humphris JL, Johns AL, Simpson SH, Cowley MJ, Pajic M, Chang DK, Nagrial AM, Chin VT, Chantrill LA, Pinese M, et al: Australian Pancreatic Cancer Genome Initiative: Clinical and pathologic features of familial pancreatic cancer. Cancer. 120:3669–3675. 2014. View Article : Google Scholar : PubMed/NCBI
11	Vazquez F, Ramaswamy S, Nakamura N and Sellers WR: Phosphorylation of the PTEN tail regulates protein stability and function. Mol Cell Biol. 20:5010–5018. 2000. View Article : Google Scholar : PubMed/NCBI
12	Yamaguchi K, Okusaka T, Shimizu K, Furuse J, Ito Y, Hanada K and Shimosegawa T: Committee for revision of clinical guidelines for pancreatic cancer of Japan Pancreas Society: EBM-based Clinical Guidelines for Pancreatic Cancer (2013) issued by the Japan Pancreas Society: A synopsis. Jpn J Clin Oncol. 44:883–888. 2014. View Article : Google Scholar : PubMed/NCBI
13	Zhan HX, Xu JW, Wu D, Zhang TP and Hu SY: Pancreatic cancer stem cells: new insight into a stubborn disease. Cancer Lett. 357:429–437. 2015. View Article : Google Scholar : PubMed/NCBI
14	Limani P, Samaras P, Lesurtel M, Graf R, DeOliveira ML, Petrowsky H and Clavien PA: Pancreatic cancer - a curable disease. Praxis (Bern 1994). 104:453–460. 2015. View Article : Google Scholar : PubMed/NCBI
15	Grant RC, Selander I, Connor AA, Selvarajah S, Borgida A, Briollais L, Petersen GM, Lerner-Ellis J, Holter S and Gallinger S: Prevalence of germline mutations in cancer predisposition genes in patients with pancreatic cancer. Gastroenterology. 148:556–564. 2015. View Article : Google Scholar : PubMed/NCBI
16	Huang M, Tang SN, Upadhyay G, Marsh JL, Jackman CP, Srivastava RK and Shankar S: Rottlerin suppresses growth of human pancreatic tumors in nude mice, and pancreatic cancer cells isolated from Kras(G12D) mice. Cancer Lett. 353:32–40. 2014. View Article : Google Scholar : PubMed/NCBI
17	Stewart DJ, Nunez MI, Jelinek J, Hong D, Gupta S, Aldaz M, Issa JP, Kurzrock R and Wistuba II: Impact of decitabine on immunohistochemistry expression of the putative tumor suppressor genes FHIT, WWOX, FUS1 and PTEN in clinical tumor samples. Clin Epigenetics. 6:132014. View Article : Google Scholar : PubMed/NCBI
18	Nakanishi A, Kitagishi Y, Ogura Y and Matsuda S: The tumor suppressor PTEN interacts with p53 in hereditary cancer (Review). Int J Oncol. 44:1813–1819. 2014.PubMed/NCBI
19	Suda T, Oba H, Takei H, Kurosumi M, Hayashi S and Yamaguchi Y: ER-activating ability of breast cancer stromal fibroblasts is regulated independently of alteration of TP53 and PTEN tumor suppressor genes. Biochem Biophys Res Commun. 428:259–263. 2012. View Article : Google Scholar : PubMed/NCBI
20	Kim SJ, Jung HJ and Lim CJ: Reactive oxygen species-dependent down-regulation of tumor suppressor genes PTEN, USP28, DRAM, TIGAR, and CYLD under oxidative stress. Biochem Genet. 51:901–915. 2013. View Article : Google Scholar : PubMed/NCBI
21	Lang Y, Xu S, Ma J, Wu J, Jin S, Cao S and Yu Y: MicroRNA-429 induces tumorigenesis of human non-small cell lung cancer cells and targets multiple tumor suppressor genes. Biochem Biophys Res Commun. 450:154–159. 2014. View Article : Google Scholar : PubMed/NCBI
22	Yang H, Chen H, Qiu Z, et al: Preliminary screening of drug resistance-related genes downstream of STAT3 in human pancreatic cancer cell. Chin J Gen Surg. 20:925–930. 2011.
23	Gautam A, Li ZR and Bepler G: RRM1-induced metastasis suppression through PTEN-regulated pathways. Oncogene. 22:2135–2142. 2003. View Article : Google Scholar : PubMed/NCBI
24	Hayashi Y, Kajikawa M, Matsumoto T and Okada N: Mechanism by which a LINE protein recognizes its 3′ tail RNA. Nucleic Acids Res. 42:10605–10617. 2014. View Article : Google Scholar : PubMed/NCBI
25	Camenares D, Dulebohn DP, Svetlanov A and Karzai AW: Active and accurate trans-translation requires distinct determinants in the C-terminal tail of SmpB protein and the mRNA-like domain of transfer messenger RNA (tmRNA). J Biol Chem. 288:30527–30542. 2013. View Article : Google Scholar : PubMed/NCBI
26	Vallazza B, Petri S, Poleganov MA, Eberle F, Kuhn AN and Sahin U: Recombinant messenger RNA technology and its application in cancer immunotherapy, transcript replacement therapies, pluripotent stem cell induction, and beyond. Wiley Interdiscip Rev RNA. 6:471–499. 2015.(In Chinese). View Article : Google Scholar : PubMed/NCBI
27	Yi X, Jiang T, Zhai H, et al: Experimental study of lentiviral vector intermediate RNAi target on inhibiting the expression of pancreatic cancer cell survivin and its effect in inducing cell apoptosis. Chin J Gen Surg. 19:227–233. 2010.(In Chinese).
28	Xiang C, Zheng Y and Shi Z: The influence of the expression change of microRNA-10b on biological behavior of pancreatic cancer cell. Chin J Gen Surg. 21:1091–1092. 2012.